{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:14:27Z","timestamp":1783977267800,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-022-05213-1","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T11:04:03Z","timestamp":1663758243000},"page":"147-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Drug retention rate and predictive factors of drug survival for secukinumab in radiographic axial spondyloarthritis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4409-059X","authenticated-orcid":false,"given":"Berkan","family":"Arma\u011fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1064-9690","authenticated-orcid":false,"given":"Levent","family":"K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-1103","authenticated-orcid":false,"given":"Bayram","family":"Fariso\u011fullar\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9543-4685","authenticated-orcid":false,"given":"G\u00f6zde K\u00fcbra","family":"Yard\u0131mc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2260-4660","authenticated-orcid":false,"given":"Emre","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-2813","authenticated-orcid":false,"given":"Ertu\u011frul \u00c7a\u011fr\u0131","family":"B\u00f6lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-3117","authenticated-orcid":false,"given":"\u00d6mer","family":"Karada\u011f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8208-1585","authenticated-orcid":false,"given":"\u015eule Apra\u015f","family":"Bilgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2802-6061","authenticated-orcid":false,"given":"Sedat","family":"Kiraz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3904-0769","authenticated-orcid":false,"given":"\u0130hsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-2109","authenticated-orcid":false,"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"26","key":"5213_CR1","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog JD, Chhabra A, Colbert RA (2016) Ankylosing spondylitis and axial spondyloarthritis. N Engl J Med 374(26):2563\u20132574. https:\/\/doi.org\/10.1056\/NEJMra1406182","journal-title":"N Engl J Med"},{"issue":"6","key":"5213_CR2","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5213_CR3","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/art.41042","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA et al (2019) 2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 71(10):1599\u20131613. https:\/\/doi.org\/10.1002\/art.41042","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"5213_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1517\/14712598.2016.1167183","volume":"6","author":"J Braun","year":"2016","unstructured":"Braun J, Baraliakos X, Kiltz U (2016) Secukinumab (AIN457) in the treatment of ankylosing spondylitis. Expert Opin Biol Ther 6(5):711\u2013722. https:\/\/doi.org\/10.1517\/14712598.2016.1167183","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"5213_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/nrrheum.2016.7","volume":"12","author":"JH Duarte","year":"2016","unstructured":"Duarte JH (2016) Spondyloarthropathies: IL-17A blockade ameliorates ankylosing spondylitis. Nat Rev Rheumatol 12(2):72. https:\/\/doi.org\/10.1038\/nrrheum.2016.7","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"5213_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/1756-185X.13094","volume":"20","author":"JC Wei","year":"2017","unstructured":"Wei JC, Baeten D, Sieper J, Deodhar A, Bhosekar V, Martin R et al (2017) Efficacy and safety of secukinumab in Asian patients with active ankylosing spondylitis: 52-week pooled results from two phase 3 studies. Int J Rheum Dis 20(5):589\u2013596. https:\/\/doi.org\/10.1111\/1756-185X.13094","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"5213_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000592","volume":"3","author":"H Marzo-Ortega","year":"2017","unstructured":"Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Delicha EM et al (2017) Secukinumab provides sustained improvements in the signs and symptoms of active ankylosing spondylitis with high retention rate: 3-year results from the phase III trial, MEASURE 2. RMD Open 3(2):e000592. https:\/\/doi.org\/10.1136\/rmdopen-2017-000592","journal-title":"RMD Open"},{"issue":"2","key":"5213_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001005","volume":"5","author":"X Baraliakos","year":"2019","unstructured":"Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H et al (2019) Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open 5(2):e001005. https:\/\/doi.org\/10.1136\/rmdopen-2019-001005","journal-title":"RMD Open"},{"issue":"1","key":"5213_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/14728214.2015.993378","volume":"20","author":"J Braun","year":"2015","unstructured":"Braun J, Kiltz U, Heldmann F, Baraliakos X (2015) Emerging drugs for the treatment of axial and peripheral spondyloarthritis. Expert Opin Emerg Drugs 20(1):1\u201314. https:\/\/doi.org\/10.1517\/14728214.2015.993378","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"5213_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s40265-019-01075-3","volume":"79","author":"HA Blair","year":"2019","unstructured":"Blair HA (2019) Secukinumab: a review in ankylosing spondylitis. Drugs 79(4):433\u2013443. https:\/\/doi.org\/10.1007\/s40265-019-01075-3","journal-title":"Drugs"},{"issue":"7","key":"5213_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1080\/14712598.2019.1605352","volume":"19","author":"M Torgutalp","year":"2019","unstructured":"Torgutalp M, Poddubnyy D (2019) IL-17 inhibition in axial spondyloarthritis: current and future perspectives. Expert Opin Biol Ther 19(7):631\u2013641. https:\/\/doi.org\/10.1080\/14712598.2019.1605352","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"5213_CR12","first-page":"438","volume":"20","author":"S Gentileschi","year":"2018","unstructured":"Gentileschi S, Vitale A, Rigante D, Lopalco G, Emmi G, Orlando I et al (2018) Prompt clinical response to secukinumab in patients with axial spondyloarthritis: real life observational data from three Italian referral centers. Isr Med Assoc J 20(7):438\u2013441","journal-title":"Isr Med Assoc J"},{"issue":"13","key":"5213_CR13","doi-asserted-by":"publisher","first-page":"1759720X2110090","DOI":"10.1177\/1759720X211009021","volume":"2021","author":"OC Kwon","year":"2021","unstructured":"Kwon OC, Park JH, Park MC (2021) Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor. Ther Adv Musculoskelet Dis 2021(13):1759720X211009021. https:\/\/doi.org\/10.1177\/1759720X211009021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"7","key":"5213_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s11926-019-0830-0","volume":"21","author":"P Mease","year":"2019","unstructured":"Mease P (2019) Emerging immunomodulatory therapies and new treatment paradigms for axial spondyloarthritis. Curr Rheumatol Rep 21(7):35. https:\/\/doi.org\/10.1007\/s11926-019-0830-0","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"5213_CR15","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/annrheumdis-2013-203582","volume":"74","author":"C Stolwijk","year":"2015","unstructured":"Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A (2015) Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis 74(1):65\u201373. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203582","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5213_CR16","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3906\/sag-2007-123","volume":"51","author":"E Bilgin","year":"2021","unstructured":"Bilgin E, Ceylan F, Duran E, Farisogullari B, Bolek EC, Yardimci GK et al (2021) Efficacy, retention, and safety of tofacitinib in real-life: Hur-bio monocentric experience. Turk J Med Sci 51(1):297\u2013308. https:\/\/doi.org\/10.3906\/sag-2007-123","journal-title":"Turk J Med Sci"},{"issue":"4","key":"5213_CR17","first-page":"609","volume":"38","author":"E Bilgin","year":"2020","unstructured":"Bilgin E, Farisogullari B, Armagan B, Sari A, Yardimci GK, Bolek EC et al (2020) Predictors of drug retention and treatment response in axial spondyloarthritis patients treated with certolizumab: real-life results from the HURBIO registry. Clin Exp Rheumatol 38(4):609\u2013614","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5213_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Van derLinden","year":"1984","unstructured":"Van derLinden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5213_CR19","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00296-003-0432-y","volume":"25","author":"Y Akkoc","year":"2005","unstructured":"Akkoc Y, Karatepe AG, Akar S, Kirazli Y, Akkoc N (2005) A Turkish version of the bath ankylosing spondylitis disease activity index: reliability and validity. Rheumatol Int 25(4):280\u2013284. https:\/\/doi.org\/10.1007\/s00296-003-0432-y","journal-title":"Rheumatol Int"},{"issue":"1","key":"5213_CR20","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10067-004-0968-6","volume":"24","author":"B Yanik","year":"2005","unstructured":"Yanik B, G\u00fcrsel YK, Kutlay S, Ay S, Elhan AH (2005) Adaptation of the bath ankylosing spondylitis functional index to the Turkish population, its reliability and validity: functional assessment in AS. Clin Rheumatol 24(1):41\u201347. https:\/\/doi.org\/10.1007\/s10067-004-0968-6","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5213_CR21","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1007\/s10067-020-04944-5","volume":"39","author":"T Williams","year":"2020","unstructured":"Williams T, Wadeley A, Bond D, Cavill C, Freeth M, Sengupta R (2020) Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases. Bath Clin Rheumatol 39(5):1501\u20131504. https:\/\/doi.org\/10.1007\/s10067-020-04944-5","journal-title":"Bath Clin Rheumatol"},{"key":"5213_CR22","doi-asserted-by":"publisher","first-page":"6983272","DOI":"10.1155\/2020\/6983272","volume":"2020","author":"S Gentileschi","year":"2020","unstructured":"Gentileschi S, Rigante D, Sota J, Lopalco G, Giannotta MG, Emmi G et al (2020) Long-term effectiveness of secukinumab in patients with axial spondyloarthritis. Mediators Inflamm 2020:6983272. https:\/\/doi.org\/10.1155\/2020\/6983272","journal-title":"Mediators Inflamm"},{"issue":"3","key":"5213_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001280","volume":"6","author":"B Michelsen","year":"2020","unstructured":"Michelsen B, Lindstrom U, Codreanu C, Ciurea A, Zavada J, Loft AG et al (2020) Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration. RMD Open 6(3):e001280. https:\/\/doi.org\/10.1136\/rmdopen-2020-001280","journal-title":"RMD Open"},{"key":"5213_CR24","doi-asserted-by":"crossref","unstructured":"Argum\u00e1nez CM EV, Mart\u00edn M, Valero M, Bachiller-Corral J, Joven-Ib\u00e1\u00f1ez B et al (2019) Secukinumab for axial spondyloarthritis: drug survival in real-world setting and response factors. Annals of the Rheumatic Diseases webpage. https:\/\/ard.bmj.com\/content\/78\/Suppl_2\/887.1. Accessed 10 Mar 2020.","DOI":"10.1136\/annrheumdis-2019-eular.7874"},{"issue":"2","key":"5213_CR25","first-page":"342","volume":"37","author":"HF Mann","year":"2019","unstructured":"Mann HF, Zavada J, Senolt L, Bubova K, Nekvindova L, Kristkova Z et al (2019) Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry. Clin Exp Rheumatol 37(2):342\u2013343","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"5213_CR26","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s40744-022-00446-9","volume":"9","author":"MJ Moreno-Ramos","year":"2022","unstructured":"Moreno-Ramos MJ, Sanchez-Piedra C, Mart\u00ednez-Gonz\u00e1lez O, Rodr\u00edguez-Lozano C, P\u00e9rez-Garcia C, Freire M, Campos C, C\u00e1liz-Caliz R, Calvo J, Blanco-Madrigal JM, P\u00e9rez-G\u00f3mez A, Moreno-Mart\u00ednez MJ, Linares L, S\u00e1nchez-Alonso F, Sastr\u00e9 C, Castrej\u00f3n I (2022) Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the Spanish BIOBADASER Registry. Rheumatol Ther 9(4):1031\u20131047. https:\/\/doi.org\/10.1007\/s40744-022-00446-9","journal-title":"Rheumatol Ther"},{"issue":"10","key":"5213_CR27","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1007\/s10067-017-3585-x","volume":"36","author":"YX Lee","year":"2017","unstructured":"Lee YX, Kwan YH, Png WY, Lim KK, Tan CS, Lui NL et al (2017) Association of obesity with patient-reported outcomes in patients with axial spondyloarthritis: a cross-sectional study in an urban Asian population. Clin Rheumatol 36(10):2365\u20132370. https:\/\/doi.org\/10.1007\/s10067-017-3585-x","journal-title":"Clin Rheumatol"},{"issue":"4","key":"5213_CR28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/00365528309181627","volume":"18","author":"H Ostensen","year":"1983","unstructured":"Ostensen H, Burhol PG, Heger J (1983) Gastric cascade: a diagnosis without clinical importance? Scand J Gastroenterol 18(4):487\u2013489","journal-title":"Scand J Gastroenterol"},{"issue":"12","key":"5213_CR29","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.3899\/jrheum.120595","volume":"39","author":"L Durcan","year":"2012","unstructured":"Durcan L, Wilson F, Conway R, Cunnane G, O\u2019Shea FD (2012) Increased body mass index in ankylosing spondylitis is associated with greater burden of symptoms and poor perceptions of the benefits of exercise. J Rheumatol 39(12):2310\u20132314. https:\/\/doi.org\/10.3899\/jrheum.120595","journal-title":"J Rheumatol"},{"issue":"1","key":"5213_CR30","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jbspin.2019.09.003","volume":"87","author":"J Shan","year":"2019","unstructured":"Shan J, Zhang J (2019) Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine 87(1):103\u2013104. https:\/\/doi.org\/10.1016\/j.jbspin.2019.09.003","journal-title":"Joint Bone Spine"},{"issue":"10","key":"5213_CR31","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","volume":"71","author":"S Alzabin","year":"2012","unstructured":"Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K et al (2012) Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway. Ann Rheum Dis 71(10):1741\u20131748. https:\/\/doi.org\/10.1136\/annrheumdis-2011-201024","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"5213_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.3858\/emm.2012.44.7.047","volume":"44","author":"JY Jhun","year":"2012","unstructured":"Jhun JY, Yoon BY, Park MK, Oh HJ, Byun JK, Lee SY et al (2012) Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation. Exp Mol Med 44(7):424\u2013431. https:\/\/doi.org\/10.3858\/emm.2012.44.7.047","journal-title":"Exp Mol Med"},{"issue":"5","key":"5213_CR33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1093\/rheumatology\/ket433","volume":"53","author":"E Gremese","year":"2014","unstructured":"Gremese E, Bernardi S, Bonazza S, Nowik M, Peluso G, Massara A et al (2014) Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. Rheumatology (Oxford) 53(5):875\u2013881. https:\/\/doi.org\/10.1093\/rheumatology\/ket433","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"5213_CR34","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1186\/ar3841","volume":"14","author":"S Ottaviani","year":"2012","unstructured":"Ottaviani S, Allanore Y, Tubach F, Forien M, Gardette A, Pasquet B et al (2012) Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 14(3):R115. https:\/\/doi.org\/10.1186\/ar3841","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"5213_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3899\/jrheum.150648","volume":"43","author":"F Maas","year":"2016","unstructured":"Maas F, Arends S, van der Veer E, Wink F, Efde M, Bootsma H et al (2016) Obesity is common in axial spondyloarthritis and is associated with poor clinical outcome. J Rheumatol 43(2):383\u2013387. https:\/\/doi.org\/10.3899\/jrheum.150648","journal-title":"J Rheumatol"},{"issue":"26","key":"5213_CR36","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an interleukin-17A inhibitor, in Ankylosing Spondylitis. N Engl J Med 373(26):2534\u20132548. https:\/\/doi.org\/10.1056\/NEJMoa1505066","journal-title":"N Engl J Med"},{"issue":"6","key":"5213_CR37","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070\u20131077. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209730","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5213_CR38","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13075-019-1882-2","volume":"21","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A et al (2019) Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 21(1):111. https:\/\/doi.org\/10.1186\/s13075-019-1882-2","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5213_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-002106","volume":"8","author":"M Dougados","year":"2022","unstructured":"Dougados M, Lucas J, Desfleurs E, Lukas C, Saraux A, Tournadre A, Ruyssen-Witrand A, Wendling D, Goupille P, Claudepierre P (2022) Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France. RMD Open 8(1):e002106. https:\/\/doi.org\/10.1136\/rmdopen-2021-002106","journal-title":"RMD Open"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05213-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05213-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,13]],"date-time":"2023-01-13T11:10:06Z","timestamp":1673608206000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05213-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["5213"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05213-1","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"20 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by local ethics committee and performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}